OncoCyte Co. (OCX) Short Interest Update

OncoCyte Co. (NYSEAMERICAN:OCX) saw a significant increase in short interest in the month of January. As of January 12th, there was short interest totalling 570,212 shares, an increase of 19.5% from the December 29th total of 477,222 shares. Based on an average trading volume of 26,062 shares, the short-interest ratio is currently 21.9 days. Currently, 6.8% of the shares of the company are short sold.

Shares of OncoCyte (OCX) traded up $0.05 during trading hours on Wednesday, hitting $4.45. The stock had a trading volume of 8,400 shares, compared to its average volume of 21,913. OncoCyte has a 12 month low of $3.60 and a 12 month high of $7.85. The company has a market capitalization of $131.99 and a PE ratio of -7.18.

OncoCyte (NYSEAMERICAN:OCX) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01.

A hedge fund recently raised its stake in OncoCyte stock. Broadwood Capital Inc. lifted its stake in OncoCyte Co. (NYSEAMERICAN:OCX) by 17.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,596,680 shares of the biotechnology company’s stock after buying an additional 540,000 shares during the period. OncoCyte makes up approximately 4.5% of Broadwood Capital Inc.’s investment portfolio, making the stock its 5th biggest position. Broadwood Capital Inc. owned about 11.48% of OncoCyte worth $27,155,000 as of its most recent SEC filing.

A number of brokerages have recently issued reports on OCX. ValuEngine cut OncoCyte from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. Zacks Investment Research cut OncoCyte from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/24/oncocyte-co-ocx-short-interest-update.html.

About OncoCyte

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply